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In sub-Saharan Africa there is a disproportionate 
burden of HIV in young women [1]. Microbicides 
are products that can be applied to the vagina or 
rectum with the intention of reducing the acqui-
sition of sexually transmitted infections, includ-
ing HIV, in women. If proven to be effective at 
reducing incident HIV infections, microbicides 
could fill an important HIV prevention gap, 
especially for those women who are unable to 
successfully negotiate mutual monogamy or con-
dom use. Microbicides have the potential to alter 
the  trajectory of the HIV epidemic in southern 
Africa [2]. 
To date, every effectiveness trial of candidate 
microbicides has shown no impact on HIV 
acquisition [3–8]. Indeed, trials of two products, 
COL-1492 [7] and cellulose sulfate [8], showed 
trends toward increased risk of HIV infection. 
The recently completed HIV Prevention Trials 
Network (HPTN) 035 trial of 0.5% PRO 
2000 gel demonstrated a modest 30% reduc-
tion in HIV incidence in a four-arm study 
of 3099 women with 87 HIV infections in 
the PRO 2000 and placebo arms of this trial 
(risk ratio: 0.70) [9]. However, this effect on 
HIV infection was not statistically significant 
(p = 0.1). Subsequent findings from the almost 
threefold larger Microbicide Development 
Program (MDP) 301 trial, which had 0.5% 
PRO 2000 and placebo groups comprising 6268 
women with 253 HIV infections, showed that 
0.5% PRO 2000 had no protective effect against 
HIV infection (risk ratio: 1.05) [101]. 
How should the different outcomes from 
these two trials be interpreted?
There are three scenarios worthy of exploration. 
In scenario one, where PRO 2000 has no protec-
tive effect against HIV infection, both the MDP 
301 trial and HPTN 035 trial results could be 
interpreted as being consistent with this outcome 
since the 95% confidence intervals of the risk 
ratios for both trials included zero effect. In this 
case, the point estimate of 5% increase in HIV 
incidence observed in the 0.5% PRO 2000 group 
of the MDP 301 trial and the point estimate of 
30% reduction in HIV incidence observed in 
the 0.5% PRO 2000 group of the HPTN 035 
trial is variability due purely to chance. While 
the observed effect in the HPTN 035 trial is suf-
ficiently distant from zero effect to suggest that 
PRO 2000 may have some benefit, the p-value of 
0.10 meant that there was still an unacceptably 
high likelihood that PRO 2000 is not effective 
at all.
In scenario two, PRO 2000 has a moderate 
protective effect against HIV infection. A moder-
ate effect of up to 18% protection is not inconsis-
tent with the results of the two trials as this level 
of protection is within the upper bounds of the 
95% confidence intervals of the risk ratios from 
both studies. 
In scenario three, PRO 2000 has a substan-
tial protective effect against HIV infection of, 
say, 55%. In this scenario, both trials may have 
produced underestimates of the ‘true’ effect. The 
upper bounds of the 95% confidence intervals of 
the risk ratios from both trials exclude this level 
of effect. While this scenario is unlikely, if it did 
occur, the underestimate would be most likely 
due to suboptimal adherence. Inadequate adher-
ence, especially in relation to exposure to HIV, is 
one of the most serious threats that could under-
mine a microbicide trial’s ability to demonstrate 
an accurate level of efficacy of the product [10]. In 
microbicide trials, the effectiveness of a product 
is dependent on both the efficacy of the product 
and the participants’ willingness and ability to use 
the product as instructed. For example, trials with 
only 50% adherence will be able to demonstrate, 
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at most, half the true efficacy of a short-acting 
product such as PRO 2000. Measuring adherence 
is also challenging and although current clinical 
trials all include some form of assessment of prod-
uct use, measures such as self-reported behavior 
can  sometimes be unreliable. 
Each of these scenarios provides a perspective 
on how the results of the HPTN 035 and MDP 
301 trials can be interpreted. Taken together, 
the results of the HPTN 035 and MDP 301 tri-
als suggest that, although safe, 0.5% PRO 2000 
gel may have little or no effect on reducing a 
woman’s risk of HIV infection during typical 
use and that this product is not worth pursuing 
further as a potential microbicide. This outcome 
was particularly disappointing as 0.5% PRO 
2000 has potent activity against HIV in vitro 
[11–13] and in animal models for vaginal HIV 
 transmission [14,15]. 
What lessons can be learnt for future 
microbicides trials?
First, these results raise a question about the 
usefulness of animal models that showed PRO 
2000 had a protective effect. Second, these 
results highlight the fundamental challenges 
faced in determining which products warrant 
proceeding into human efficacy trials in the 
absence of a surrogate marker of protection. 
Third, adherence and measurement thereof is 
fundamentally important in microbicide trials 
in order to exclude scenario three. Studies assess-
ing new formulations, such as vaginal rings, to 
improve adherence are needed. Fourth, both 
trials achieved their objective; the HPTN 035 
study as a screening Phase IIb trial and the 
MDP 301 study as a Phase III trial have together 
addressed the question of whether PRO 2000 is 
effective in preventing HIV infection following 
typical use. Finally, as much as we need a series 
of human studies looking at effectiveness of 
products, we also need to build into these stud-
ies a program of basic science research to iden-
tify potential surrogate markers of protection. 
Without a validated criterion to decide whether 
a product should proceed, the microbicides 
field is hamstrung with doing either relatively 
large expensive screening trials or proceeding 
straight to even larger and often substantially 
more expensive Phase III trials.
Despite numerous scientific, ethical and meth-
odological challenges, microbicides provide real 
potential to influence the course of the HIV 
epidemic as they could fill an important gap for 
women-initiated prevention methods. The joint 
results of the HPTN 035 and MDP 301 trials 
have closed a chapter in microbicide development 
by being the last studies on polymers as candidate 
microbicides. Attention is now firmly focused on 
antiretroviral agents for topical use as candidate 
microbicides with results on tenofovir gel due for 
release in mid 2010. 
Questions that remain to be answered include:
n	When an effective microbicide is found, what 
data will be needed to address the main obsta-
cles to widespread use; for example, safety in 
pregnancy, long-term safety, safety in very 
high-frequency use, approaches to increase 
over-the-counter access to the product, messag-
ing to promote uptake and disposable, 
low-cost applicators?
n	What are the most appropriate correlates 
of protection?
n	Which formulation of microbicides will be 
most acceptable (e.g., gel, vaginal ring or film)?
n	How should a microbicide product be 
formulated to promote adherence?
The interpretation of these upcoming results 
on tenofovir gel will benefit enormously from the 
lessons learnt from the HPTN 035 and MDP 
301 trials.
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